TERT and metabolic dysfunction-associated steatotic liver disease: Our recent report highlighted the better performance of TERT C228T in serum cfDNA than AFP and PIVKAII in the early diagnosis of primary liver cancer in patients with non-alcoholic fatty live disease (NAFLD) [8].